Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.56 |
| ▸ | CA12 | O43570 | 12/20 | 0.55 |
| ▸ | CA9 | Q16790 | 11/20 | 0.55 |
| ▸ | CA1 | P00915 | 5/20 | 0.51 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | TDO2 | P48775 | 1/20 | 0.44 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3940608 | 0.86 | CA12 (0.76) | HDAC1HDAC2CA12CA9CA1 | |
| SCHEMBL3937520 | 0.85 | HDAC1 (0.77) | HDAC1HDAC2CA12CA9CA1 | |
| SCHEMBL4029124 | 0.82 | MEN1 (0.57) | HDAC1HDAC2CA12CA9CA2 | |
| SCHEMBL31753078 | 0.74 | KMT2A (0.74) | HDAC1CA12CA9CA1PPARA | |
| SCHEMBL916927 | 0.74 | KMT2A (0.74) | HDAC1CA12CA9CA1PPARA | |
| SCHEMBL7280334 | 0.74 | CA12 (0.65) | HDAC1HDAC2CA12CA9CA1 | |
| SCHEMBL13606246 | 0.74 | HDAC1 (0.73) | HDAC1HDAC2CA12CA9CA1 | |
| SCHEMBL9168762 | 0.72 | RAB9A (0.86) | CA12CA9CA1CA2KMT2A | |
| SCHEMBL3937523 | 0.72 | HDAC1 (1.00) | HDAC1HDAC2CA12CA9CA1 | |
| SCHEMBL31752672 | 0.72 | CA12 (0.70) | HDAC1HDAC2CA12CA9CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312377-A1 | DERIVATIVES OF BENZO[D]ISOTHIAZOLES AS HISTONES DEACETYLASE INHIBITORS | UNIVERSIDAD DE GRANADA (ES) | 2009-12-17 | — | — | US | disclosed |
| EP-2045246-A1 | DERIVATIVES OF BENZO[D] ISOTHIAZOLES AS HISTONE DEACETYLASE INHIBITORS | Universidad De Granada (ES) | 2009-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312377-A1 | DERIVATIVES OF BENZO[D]ISOTHIAZOLES AS HISTONES DEACETYLASE INHIBITORS | HDAC1, HDAC2, HDAC3 | HDAC1 1/4885HDAC2 2/4885CA12 3053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.